Even though we did not test the expression of NKp46 ligands on patient-derived tumor cells, our results using DM6 cells suggest that blockade NKG2D is relatively more important than NKp46 to inhibit anti-melanoma responses of NK cells. Here, KLRK1 is linked to melanoma.